Results 11 to 20 of about 4,771 (191)

Hematologic toxicity is rare in relapsed patients treated with belinostat: a systematic review of belinostat toxicity and safety in peripheral T-cell lymphomas

open access: yesCancer Management and Research, 2018
Pamela B Allen, Mary Jo Lechowicz Department of Hematology and Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA Abstract: Peripheral T-cell lymphomas (PTCLs) are an aggressive and diverse group of lymphomas with a T-cell origin ...
Allen PB, Lechowicz MJ
doaj   +6 more sources

Apoptotic effect of Belinostat (PXD101) on MCF-7 cancer cells [PDF]

open access: yesAnnals of Medical Research, 2021
Aim: Breast cancer continues to be the most common type of cancer among women. Recent development in epigenomics hashighlighted key mechanisms in which epigenetic regulation contributes to cancer treatment. Epigenetic modulating drugs promises novel approaches targeting cancer treatment. Belinostat is a histone deacetylase inhibitor approved by the U.S.
TUNCER, Zeliha   +3 more
openaire   +3 more sources

Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients. [PDF]

open access: yesPLoS ONE, 2013
UnlabelledBelinostat is a hydroxamate class HDAC inhibitor that has demonstrated activity in peripheral T-cell lymphoma and is undergoing clinical trials for non-hematologic malignancies.
Ling-Zhi Wang   +16 more
doaj   +2 more sources

Thermodynamic and transport properties of Belinostat

open access: yesBibechana
HDACs inhibitors, Belinostat inhibits class I HDACs, class II HDACs and class IV HDAC proteins activities. Antitumor activity of Belinostat is attributed to epi- genetic control of gene expression and inhibition of protein repression.
Narayan Gautam   +4 more
doaj   +4 more sources

The Development of an Effective Synthetic Route of Belinostat

open access: yesOrganic Process Research & Development, 2016
A practical synthetic route of belinostat is reported. Belinostat was obtained via a five-step process starting from benzaldehyde and including addition reaction with sodium bisulfite, sulfochlorination with chlorosulfonic acid, sulfonamidation with aniline, Knoevenagel condensation, and the final amidation with hydroxylamine.
Xuefei Bao   +4 more
openaire   +2 more sources

Mutant Isocitrate Dehydrogenase 1 Expression Enhances Response of Gliomas to the Histone Deacetylase Inhibitor Belinostat

open access: yesTomography, 2023
Histone deacetylase inhibitors (HDACis) are drugs that target the epigenetic state of cells by modifying the compaction of chromatin through effects on histone acetylation.
Chi-Ming Chang   +7 more
doaj   +2 more sources

Monitoring the effect of belinostat in solid tumors by H4 acetylation [PDF]

open access: yesAPMIS, 2008
Histone deacetylase (HDAC) inhibition is a novel entity in medical oncology, and several HDAC inhibitors are in clinical trials. One of them is the hydroxamic acid belinostat (PXD101) that has demonstrated therapeutic efficacy for several clinical indications.
Marquard, L.   +5 more
core   +4 more sources

Improving the Thrombocytopenia Adverse Reaction of Belinostat Using Human Serum Albumin Nanoparticles [PDF]

open access: yesInternational Journal of Nanomedicine
Jia-Yu Liu,1 Chia-Hung Yen,2,3 Ya-Fan Lin,4 Yin-Hsun Feng,5 Yi-Ping Fang1,6,7 1School of Pharmacy, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan; 2Graduate Institute of Natural Products, College of Pharmacy, Kaohsiung Medical ...
Liu JY, Yen CH, Lin YF, Feng YH, Fang YP
doaj   +1 more source

Experimental in vivo and in vitro treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer

open access: yesBMC Cancer, 2012
Background Treatment options for pancreatic ductal adenocarcinoma (PDAC) are limited. Histone deacetylase inhibitors are a new and promising drug family with strong anticancer activity. The aim of this study was to examine the efficacy of in vitro and in
Dovzhanskiy Dmitriy I   +7 more
doaj   +2 more sources

Critical appraisal of belinostat in the management of T-cell lymphoma – patient considerations

open access: yesBlood and Lymphatic Cancer: Targets and Therapy, 2015
Andrew Bodiford,1 Mahsa S Talbott,1 Nishitha M Reddy,2 1Department of Pharmacy, 2Division of Hematology and Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA Abstract: The histone deacetylase inhibitor (HDACi ...
Bodiford A, Talbott MS, Reddy NM
doaj   +1 more source

Home - About - Disclaimer - Privacy